


WOODHEAD PUBLISHING SERIES IN BIOMEDICINE

NANOPARTICULATE DRUG DELIVERY

PERSPECTIVES ON THE TRANSITION FROM
LABORATORY TO MARKET

VANDANA PATRAVALE, PRAJAKTA DANDEKAR AND RATNESH JAIN




WP
WOODHEAD
PUBLISHING

Woodhead Publishing Series in Biomedicine: Number 17

Nanoparticulate drug delivery

*Perspectives on the transition
from the laboratory to market*

VANDANA PATRAYALE, PRAJAKTA
DANDEKAR AND RATNESH JAIN



WP

WOODHEAD
PUBLISHING



Oxford Cambridge Philadelphia New Delhi

Published by Woodhead Publishing Limited, 2012

Woodhead Publishing Limited, 80 High Street, Sawston, Cambridge, CB22 3HJ, UK
www.woodheadpublishing.com
www.woodheadpublishingonline.com

Woodhead Publishing, 1518 Walnut Street, Suite 1100, Philadelphia, PA 19102-3406, USA

Woodhead Publishing India Private Limited, G-2, Vardaan House, 7/28 Ansari Road,
Daryaganj, New Delhi – 110002, India
www.woodheadpublishingindia.com

First published in 2012 by Woodhead Publishing Limited
ISBN: 978-1-907568-98-5 (print); ISBN 978-1-908818-19-5 (online)
Woodhead Publishing Series in Biomedicine ISSN 2050-0289 (print); ISSN 2050-2097 (online)

© V. Patravale, P. Dandekar and R. Jain, 2012

The right of V. Patravale, P. Dandekar and R. Jain to be identified as authors of this Work has been asserted by them in accordance with sections 77 and 78 of the Copyright, Designs and Patents Act 1988.

British Library Cataloguing-in-Publication Data: A catalogue record for this book is available from the British Library.

Library of Congress Control Number: 2012946289

All rights reserved. No part of this publication may be reproduced, stored in or introduced into a retrieval system, or transmitted, in any form, or by any means (electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of the Publishers. This publication may not be lent, resold, hired out or otherwise disposed of by way of trade in any form of binding or cover other than that in which it is published without the prior consent of the Publishers. Any person who does any unauthorised act in relation to this publication may be liable to criminal prosecution and civil claims for damages.

Permissions may be sought from the Publishers at the above address.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. The Publishers are not associated with any product or vendor mentioned in this publication.

The Publishers and author(s) have attempted to trace the copyright holders of all material reproduced in this publication and apologise to any copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged, please write and let us know so we may rectify in any future reprint. Any screenshots in this publication are the copyright of the website owner(s), unless indicated otherwise.

Limit of Liability/Disclaimer of Warranty

The Publishers and author(s) make no representations or warranties with respect to the accuracy or completeness of the contents of this publication and specifically disclaim all warranties, including without limitation warranties of fitness of a particular purpose. No warranty may be created or extended by sales of promotional materials. The advice and strategies contained herein may not be suitable for every situation. This publication is sold with the understanding that the Publishers are not rendering legal, accounting or other professional services. If professional assistance is required, the services of a competent professional person should be sought. No responsibility is assumed by the Publishers or author(s) for any loss of profit or any other commercial damages, injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. The fact that an organisation or website is referred to in this publication as a citation and/or potential source of further information does not mean that the Publishers nor the author(s) endorse the information the organisation or website may provide or recommendations it may make. Further, readers should be aware that internet websites listed in this work may have changed or disappeared between when this publication was written and when it is read. Because of rapid advances in medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Typeset by RefineCatch Ltd, Bungay, Suffolk
Printed in the UK and USA

Nanoparticulate drug delivery

Woodhead Publishing Series in Biomedicine

- 1 Practical leadership for biopharmaceutical executives
J.Y. Chin
- 2 Outsourcing biopharma R&D to India
P.R. Chowdhury
- 3 Matlab® in bioscience and biotechnology
L. Burstein
- 4 Allergens and respiratory pollutants
Edited by M.A. Williams
- 5 Concepts and techniques in genomics and proteomics
N. Saraswathy and P. Ramalingam
- 6 An introduction to pharmaceutical sciences
J. Roy
- 7 Patently innovative: How pharmaceutical firms use emerging patent law to extend monopolies on blockbuster drugs
R.A. Bouchard
- 8 Therapeutic protein drug products: Practical approaches to formulation in the laboratory, manufacturing and the clinic
Edited by B.K. Meyer
- 9 A biotech manager's handbook: A practical guide
Edited by M. O'Neill and M.H. Hopkins
- 10 Clinical research in Asia: Opportunities and challenges
U. Sahoo
- 11 Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharma industry
W.R. Strohl and L.M. Strohl
- 12 Commercialising the stem cell sciences
O. Harvey
- 13
- 14 Human papillomavirus infections: From the laboratory to clinical practice
F. Cobo
- 15 Annotating new genes: From *in silico* to validations by experiments
S. Uchida
- 16 Open-source software in life science research: Practical solutions in the pharmaceutical industry and beyond
Edited by L. Harland and M. Forster

- 17 Nanoparticulate drug delivery: A perspective on the transition from laboratory to market
V. Patravale, P. Dandekar and R. Jain
- 18 Bacterial cellular metabolic systems: Metabolic regulation of a cell system with ¹³C-metabolic flux analysis
K. Shimizu
- 19 Contract research and manufacturing services (CRAMS) in India
M. Antani, G. Gokhale and K. Baxi
- 20 Bioinformatics for biomedical science and clinical applications
K-H. Liang
- 21 Deterministic versus stochastic modelling in biochemistry and systems biology
P. Lecca, I. Laurenzi and F. Jordan
- 22 Protein folding *in silico*: Protein folding versus protein structure prediction
I. Roterman-Konieczna
- 23 Computer-aided vaccine design
T.J. Chuan and S. Ranganathan
- 24 An introduction to biotechnology
W.T. Godbey
- 25 RNA interference: Therapeutic developments
T. Novobrantseva, P. Ge and G. Hinkle
- 26 Patent litigation in the pharmaceutical and biotechnology industries
G. Morgan
- 27 Clinical research in paediatric psychopharmacology: A practical guide
P. Auby
- 28 The application of SPC in the pharmaceutical and biotechnology industries
T. Cochran
- 29 Ultrafiltration for bioprocessing
H. Lutz
- 30 Therapeutic risk management of medicines
A.K. Banerjee and S. Mayall
- 31 21st century quality management and good management practices: Value added compliance for the pharmaceutical and biotechnology industry
S. Williams
- 32
- 33 CAPA in the pharmaceutical and biotech industries
J. Rodriguez
- 34 Process validation for the production of biopharmaceuticals: Principles and best practice.
A.R. Newcombe and P. Thillaivinayagalingam
- 35 Clinical trial management: An overview
U. Sahoo and D. Sawant
- 36 Impact of regulation on drug development
H. Guenter Hennings
- 37 Lean biomanufacturing
N.J. Smart
- 38 Marine enzymes for biocatalysis
Edited by A. Trincone
- 39 Ocular transporters and receptors in the eye: Their role in drug delivery
A.K. Mitra
- 40 Stem cell bioprocessing: For cellular therapy, diagnostics and drug development
T.G. Fernandes, M.M. Diogo and J.M.S. Cabral
- 41
- 42 Fed-batch fermentation: A practical guide to scalable recombinant protein production in *Escherichia coli*
G.G. Moulton and T. Vedrick

- 43 The funding of biopharmaceutical research and development
D.R. Williams
- 44 Formulation tools for pharmaceutical development
Edited by J.E.A. Diaz
- 45 Drug-biomembrane interaction studies: The application of calorimetric techniques
R. Pignatello
- 46 Orphan drugs: Understanding the rare drugs market
E. Hernberg-Ståhl
- 47 Nanoparticle-based approaches to targeting drugs for severe diseases
J.L.A. Mediano
- 48 Successful biopharmaceutical operations
C. Driscoll
- 49 Electroporation-based therapies for cancer
Edited by R. Sundarajan
- 50 Transporters in drug discovery and development
Y. Lai
- 51 The life-cycle of pharmaceuticals in the environment
R. Braund and B. Peake
- 52 Computer-aided applications in pharmaceutical technology
Edited by J. Petrović
- 53 From plant genomics to plant biotechnology
Edited by P. Poltronieri, N. Burbulis and C. Fogher
- 54 Bioprocess engineering: An introductory engineering and life science approach
K.G. Clarke
- 55 Quality assurance problem solving and training strategies for success in the pharmaceutical and life science industries
G. Welty
- 56 Nanomedicine: Prognostic and curative approaches to cancer
K. Scarberry
- 57 Gene therapy: Potential applications of nanotechnology
S. Nimesh
- 58 Controlled drug delivery: The role of self-assembling multi-task excipients
M. Mateescu
- 59 *In silico* protein design
C.M. Frenz
- 60 Bioinformatics for computer science: Foundations in modern biology
K. Revett
- 61 Gene expression analysis in the RNA world
J.Q. Clement
- 62 Computational methods for finding inferential bases in molecular genetics
Q-N. Tran
- 63 NMR metabolomics in cancer research
M. Cuperlović-Culf
- 64 Virtual worlds for medical education, training and care delivery
K. Kahol

Foreword

The topic of Nanoparticulate Drug Delivery has fascinated me for over two decades now and the one that I have enjoyed exploring in my research at the University of California, Santa Barbara over the last decade. So it is with true pleasure that I write this foreword to the book by Patravale, Dandekar and Jain on “Nanoparticulate Drug Delivery”. This book provides a very timely overview of this fascinating area at the interface of nanotechnology and medicine. It includes a very comprehensive description of the key scientific and technological issues that must be addressed before bringing nanoscale drug carriers to the market. The area of nanoparticle-based drug delivery is truly fascinating; it’s scientifically exciting, it thrives on technological innovation and holds tremendous promise for the future. Nanoparticles offer distinct advantages in pharmaceutical products by protecting the drug, targeting it to the diseased tissue and providing release at the desired rate. Implementation of this strategy in actual products, however, has proved challenging. Nanoparticles must perform several specific tasks in the body. They need to exhibit sufficient encapsulation of drugs and possess requisite material characteristics to release them at the required rate. Upon injection into the body, they must exhibit sufficiently long circulation so that they are able to accumulate at the target in necessary quantities. In order to accomplish this, they must escape clearance by the liver and other clearing organs. Upon accumulating at the target, they must be able to penetrate sufficiently deep into the tissue to fulfill their therapeutic objective. This delivery challenge is particularly significant for delicate drugs such as nucleic acids and proteins.

The challenges in designing nanoparticles have given rise to the field of nanomedicine, where researchers from a wide range of disciplines have gathered to formulate nanoparticles to meet the therapeutic objective. The book by Patravale, Dandekar and Jain does an outstanding job in providing a summary of the past efforts, current status and future directions on this field. I very much like the thoroughness, diversity and organization of the topics covered in the book. The book starts with the

design goals of nanoparticles to improve drug solubility and targeting and goes on to discuss different types of nanoparticles including polymeric systems, suspensions and dendrimers that have been designed. Subsequent chapters include a thorough discussion of various routes of administration including oral, transdermal, pulmonary and intravenous. The book also outlines methods for detailed characterization and toxicity issues. In the final chapters, the book provides key challenges associated with clinical trials and perspective from various regulatory authorities.

The book provides an excellent reference for students, professionals, researchers and educators engaged in the field of nanoparticulate drug delivery systems.

Samir Mitragotri
University of California, Santa Barbara
January 29, 2012

Contents

<i>List of figures</i>	<i>ix</i>
<i>List of tables</i>	<i>xi</i>
<i>Foreword</i>	<i>xiii</i>
1 Nanoparticulate systems as drug carriers: the need	1
1.1 Introduction: nanoparticles for drug delivery	1
1.2 Need: solubility, bioavailability, targeting and more	4
1.3 Specific nanoparticulate strategies for overcoming solubility and bioavailability limitations	5
1.4 References	21
2 Nanoparticles as drug carriers	29
2.1 Nanoparticles as drug carriers: the scope	30
2.2 Nanoparticles as drug delivery carriers	31
2.3 Application areas for nanoparticulate drug delivery systems	51
2.4 Routes of administration of nanoparticulate drug delivery systems	63
2.5 Conclusion	73
2.6 References	74
3 Characterization techniques for nanoparticulate carriers	87
3.1 Need and challenges for characterisation techniques of nanoparticulate drug carriers	88
3.2 Measuring the size of nanoparticles	91
3.3 Zeta potential measurement	96
3.4 Characterizing the morphology of the nanoparticles	100
3.5 Assessing the sterility and detecting mycoplasma or microbial contamination of nanoparticles	110
3.6 Toxicity evaluation of nanoparticles	111

3.7	Evaluating immunological potential of nanoparticles	113
3.8	References	117
4	Nanotoxicology: evaluating toxicity potential of drug-nanoparticles	123
4.1	Nanotoxicology: need towards developing safe and sustainable drug delivery systems	124
4.2	<i>In vitro</i> assays for assessing toxicity of nanoparticles	125
4.3	<i>In-vivo</i> assays for assessing toxicity of nanoparticles	130
4.4	Genotoxicity evaluation	134
4.5	References	150
5	Regulatory aspects of nanoparticulate drug delivery systems	157
5.1	Nanoparticulate drug carriers: the regulatory facet	158
5.2	Issues associated with regulating nano-drug delivery systems	160
5.3	Current approaches for regulating pharmaceutical nanocarriers	162
5.4	References	186
6	Clinical trials and industrial aspects	191
6.1	Clinical trials of nanoparticulate drug delivery systems: successes and failures	192
6.2	Case studies: cancer	195
6.3	Case studies: other diseases	202
6.4	Nanoparticulate drug delivery: an industrial outlook	204
6.5	References	205
7	Case studies: nano-systems in the market	209
7.1	Case studies: performance and market approval	209
7.2	Are nano or conventional drug delivery systems a better choice? – a market overview	214
7.3	Future perspectives on nanoparticulate drug carriers	216
7.4	References	219
	Index	221

List of figures

1.1	An overview of market progress in CNS drug development	15
2.1	Types of nanocarriers	51
3.1	The averaged ($n = 10$) intensity distribution plot (a) and correlation curve (b) for PLGA nanoparticles	93
3.2	The averaged ($n = 5$) (a) phase plot, (b) frequency plot, and (c) zeta potential distribution for PLGA nanoparticles	98
3.3	A: TEM image of Eudragit® S100 nanoparticles of curcumin; B: Cryo-TEM images of hydrogel nanoparticles of curcumin formulated using hydrophilic polymers	103
3.4	a: SEM and b: E-SEM image of polymeric nanoparticles of docetaxel formulated using a hydrophobic starch polymer	106
4.1	Bone marrow cells stained with May Grunwald–Giemsa and exhibiting the presence of micronuclei	144
4.2	(a) Normal chromosomes in rat bone marrow cells. (b and c) Various chromosomal aberrations in bone marrow cells of rats treated with CP	147
4.3	Illustrative figures indicating no comet formation in animals belonging to vehicle treated group and nanoparticle treated (a and b) and comet formation in CP treated animals (c)	150
6.1	Approval and clinical trial timelines of Sarcodoxome®	196
6.2	Clinical trial timelines of Panzem® NCD	200
6.3	Opaxio™ enters into the tumor cell via leaky vasculatures with affecting normal cells (a, b), it enters into the tumor cell (c) and digested by lysosomal enzyme cathepsin B, leads to the release of paclitaxel (d)	201
6.4	Clinical trial timelines of Opaxio™ (Xyotax)	202
6.5	Clinical trial timelines of VivaGel®	203
7.1	Geographical distribution of hepatitis A	211

7.2	Worldwide sales data of Epaxal® and other hepatitis A vaccines	213
7.3	Percentage shares of various countries/continents in the worldwide pharmaceutical market	215

List of tables

1.1	Nanoparticle formulations for poorly water soluble drugs	9
1.2	Nanoparticle based formulations for targeted cancer therapy	12
1.3	Targeted cancer therapy using nanoparticles	13
1.4	Examples of brain-targeted nanoparticles at preclinical stage	17
1.5	Examples of nanoparticulate carriers targeted to the lung	20
2.1	Types of nanocarrier products or technologies important from commercial perspective	72
3.1	Overview of methods available for characterizing nanoparticles	91
5.1	Global regulatory scenario for nanoparticulate drug delivery systems	184
6.1	Nanoparticle-based therapeutics in clinical trials	193
7.1	Comparative overview of vaccines against hepatitis A	212
7.2	Approved and upcoming new therapies for gout; 'nano' product Pegloticase expected to lead the regimen against gout	214

Nanoparticulate systems as drug carriers: the need

Abstract: Development of nanoparticles for drug delivery has progressed by leaps and bounds over the last few decades, facilitating the possibility of an efficacious therapy for some fatal diseases. This development has stemmed from either the unsuitable physicochemical characteristics of the existing drug molecules, such as limited solubility and hence poor bioavailability, or the inadequacy of the conventional delivery systems to provide safe and efficient delivery. This chapter focuses on the precise need for the development of these novel nanoparticulate drug carriers and reasons for their popularity with the drug delivery scientists. The text also discusses the various strategies, including different formulation and targeting approaches, which have been adopted to overcome the challenges presented by the inherent properties of the drug molecules. Examples of nanoparticulate drug delivery systems which have already gained market approval have been cited in the discussion, wherever applicable.

Key words: nanoparticulate drug carriers, solubility, bioavailability, targeting, nanoemulsions, nanocrystals, nanoparticles.

1.1 Introduction: nanoparticles for drug delivery

The last decade of drug delivery research has witnessed a boom in the development of the nano-drug delivery systems. The major drivers responsible for the initiation of this new revolution were the development

of a plethora of varied nano-drug delivery systems, not only by the academic institutions but also by industrial organizations. This led to the availability of a huge database comprising several research papers and patents from all over world, describing these new dosage forms. Numerous funding agencies and industries actively promoted research into nanoparticulate drug delivery vehicles and huge investments were made to this end. All these diverse and concurrent efforts created an awareness about the immense potential of these new drug delivery systems, which were then looked upon as therapeutic regimens of the future.

There are many reasons behind the development and success of nanoparticulate drug delivery systems. A few years ago, the entire attention of pharmaceutical industry was focused on the novel developments in designing various dosage forms, primarily due to expiry of the existing patents, a surfeit of poorly soluble drug candidates and the problems of non-specificity from conventional dosage forms. Under these circumstances, the development of nanoparticulate drug delivery systems gained huge momentum due to a number of diverse factors listed in the following section of this chapter.

- The pharmaceutical industries were poised to provide quality products to the patient, at the same time increasing or maintaining their profitability. However, this process demanded extensive scientific innovation and financial support. Development of new chemical entities and their transition from the laboratory to market required the company to expend as high as 800 million US dollars [1]. Apart from a huge investment, the development of the new drug was also an extensively time consuming process with very limited success rates.
- Research progress in the drug discovery area resulted in the development of various poorly soluble drug candidates. The solubility limitations of these drug candidates, in turn, lead to poor bioavailability and lower therapeutic efficacy [2, 3]. In such situations, formulation of these therapeutic molecules into nanoparticulate delivery systems was observed to improve their bioavailability and hence elicit the desired therapeutic effects from these candidates. The nanoparticles also received a prominence due to other probable benefits like biodegradability, biocompatibility, high encapsulation characteristics and probability of surface functionalization [1–3].
- Nanoparticles were found to exhibit several advantages for parenteral drug delivery; counter to the aggregation phenomenon commonly observed with microparticles, the smaller size of nanoparticles endowed them with better distribution profiles during systemic

administration. Nanoparticles enabled an effective systemic circulation, thus leading to better therapeutic outcomes. Better systemic circulation was found to be specifically important for cancer therapies, where nanoparticles could infiltrate through the vasculature of tumor tissue and provide targeted therapeutic effects [4].

- First pass metabolism is one of the key concerns for many commercial and upcoming drugs. This phenomenon accounts for their low bioavailability and reduced efficacy at the site of action. In this regard, nanoparticulate drug delivery vehicles were particularly advantageous because of their likelihood in being modulated for site specific delivery/targeted delivery. Apart from their specificity, nanoparticles were also found to mitigate drug related side effects and dose related toxicities, resulting in enhanced bioavailability of the encapsulated agent and excellent patient compliance [1, 3, 5].
- Owing to their small size, nanoparticles were found to effectively traverse many biological barriers. Of significant importance is their ability to permeate the blood brain barrier (BBB). Although brain administration is an effective route for the treatment of various brain diseases, it is severely limited due to the highly impermeable nature of the BBB. Because of their potential to cross this barrier, numerous publications have demonstrated the effectiveness of nanoparticles for targeting various central nervous system disorders [6]. Nanospectra Bioscience, Texas, USA, has recently initiated a clinical trial of nanoparticle based 'nanoshells' for the treatment of brain tumors [7].
- The size of nanoparticles offers distinct advantages when compared with conventional dosage forms. The tunable size of these systems greatly influences the release profile of the encapsulated active component, so a formulator could thus control the drug release at the site of action [8, 9].
- Nanoparticles were found to be highly versatile systems to encapsulate and delivery not only chemical drug moieties but also nucleic acid therapeutics (DNA, siRNA), and imaging and diagnostic agents, for site-specific delivery and detection. Various ligands can be attached to the surface of nanoparticles to guide them to specific locations within the body [9, 10].

Thus nanoparticulate drug carriers found applications in several diverse quarters of drug delivery research and, due to their tunable properties, they were foreseen as the future of the pharmaceutical and biotechnology industry.